Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®

  • Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer
  • PIONEER data supported filing for biosimilar filgrastim in the US
  • The abstract of the study results is published online as part of the 56th American Society of Hematology (ASH) Annual Meeting and Exposition

Holzkirchen, December 8, 2014 – Sandoz, a Novartis company, announced today Phase III data that demonstrated similarity of its investigational biosimilar filgrastim …

/by